Ceftazidime-avibactam in ceftazidime-resistant infections

Lancet Infect Dis. 2016 Sep;16(9):997-998. doi: 10.1016/S1473-3099(16)30265-1.

Authors

Yehuda Carmeli¹, Jon Armstrong², Paul Newell², Greg Stone³, Angela Wardman²

Affiliations

¹ Division of Epidemiology and the National Center for Antibiotic Resistance and Infection Control, Tel Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel. Electronic address: yehudac@tlvmc.gov.il.
² AstraZeneca, Infection GMed, Global Medicines Development, Alderley Park, Macclesfield, UK.
³ AstraZeneca, Infection GMed, Global Medicines Development, Waltham, MA, USA.

PMID: 27684334
DOI: 10.1016/S1473-3099(16)30265-1

No abstract available

Publication types

Letter
Comment

MeSH terms

Anti-Bacterial Agents
Azabicyclo Compounds*
Ceftazidime*
Drug Combinations
Humans
Microbial Sensitivity Tests
beta-Lactamase Inhibitors

Substances

Anti-Bacterial Agents
Azabicyclo Compounds
Drug Combinations
avibactam, ceftazidime drug combination
beta-Lactamase Inhibitors
Ceftazidime